JNJ-38877605 (JNJ38877605) is an orally bioavailable small-molecule inhibitor of c-Met with potential antitumor activity.

Merestinib dihydrochloride (LY-2801653) is a novel, potent, orally bioavailable, type-II ATP competitive, slow-off small molecule inhibitor of MET tyrosine kinase with a dissociation constant (Ki) of 2 nM, a pharmacodynamic residence time (Koff) of 0.00132 min(-1) and t1/2 of 525 min.

SAR125844 is a novel, potent, highly selective, reversible and ATP-competitive inhibitor of MET receptor tyrosine kinase (RTK) for intravenous administration, with an IC50 of 4.2 nM.

Tivantinib (formerly also known as ARQ-197; ARQ197), an experimental drug developed by by Arqule, Inc, is the first non-ATP-competitive, orally bioavailable and selective small molecule c-Met inhibitor with potential antineoplastic activity.

SGX-523 (SGX 523; SGX523) is a novel, exquisitely selective, and ATP-competitive inhibitor of Hepatocyte growth factor receptor/Met with potential anticancer activity.

PHA-665752 (PHA665752) is a novel, potent, selective and ATP-competitive small molecule inhibitor of c-Met Kinase with potential antitumor activity.

Glumetinib (SCC244; SCC-244; Gumarontinib) is a novel, potent and highly selective c-Met kinase inhibitor (IC50 = 0.42 nM.) with antitumor activity.

BMS-777607 (also called as BMS817378; ASLAN002) is an orally bioavailable inhibitor of the tyrosine kinase c-Met with potential antitumor activity.

SCR-1481B1 (also known as c-Met inhibitor 2) is a novel potent and selective MET inhibitor.

Capmatinib (formerly also known as INCB-28060; INC280; Tabrecta) is a novel, potent, orally bioavailable, ATP-competitive inhibitor of c-MET with potential antitumor activity.